Legend Biotech Stock

Legend Biotech EBITDA per Share

The EBITDA per Share of Legend Biotech (LEGN) as of Aug 10, 2026 is -0.74 USD. In the previous year, EBITDA per Share was -1.66 USD — a change of -55.45% (higher).

EBITDA per Share

-0.74USD

YoY

-55.45%

Last updated:

EBITDA per Share of Legend Biotech is 2026 -0.74 USD. EBITDA per Share of Legend Biotech was 2025 -1.66 USD. It decreases by -55.45% higher compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Legend Biotech Stock analysis

What does Legend Biotech do? Legend Biotech Corp is a leading biopharmaceutical company specializing in the discovery and development of innovative cell therapies for the treatment of serious diseases such as cancer. The company was founded in 2015 as a subsidiary of Genscript Biotech Corp and is headquartered in Somerset, New Jersey, USA. Additionally, the company also operates locations in China and Europe. Legend Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Legend Biotech stock

EBITDA per Share of Legend Biotech is -0.74 USD in 2026.

EBITDA per Share of Legend Biotech changed from -1.66 USD to -0.74 USD, representing a -55.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Legend Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Legend Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Legend Biotech